Design, synthesis, and biological evaluation studies of novel quinazolinone derivatives as anticonvulsant agents

[1]  H. Patel,et al.  Quinazolino-benzothiazoles: fused pharmacophores as anticonvulsant agents. , 2012, European journal of medicinal chemistry.

[2]  V. Alagarsamy,et al.  Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives. , 2012, Bioorganic & medicinal chemistry letters.

[3]  Nagwa M. Abdel Gawad,et al.  Design, synthesis, and anticonvulsant activity of novel quinazolinone analogues , 2011 .

[4]  P. Mishra,et al.  CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones. , 2008, European journal of medicinal chemistry.

[5]  J. Chen,et al.  Synthesis and anticonvulsant evaluation of 4-(4-alkoxylphenyl)-3-ethyl-4H-1,2,4-triazoles as open-chain analogues of 7-alkoxyl-4,5-dihydro[1,2,4]triazolo[4,3-a]quinolines. , 2007, Bioorganic & medicinal chemistry.

[6]  William E. Klunk,et al.  Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives , 2007, Journal of Molecular Neuroscience.

[7]  M. Rogawski.  Point–Counterpoint: Do Interictal Spikes Trigger Seizures or Protect against Them? , 2006, Epilepsy currents.

[8]  P. Yogeeswari,et al.  Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. , 2005, Journal of medicinal chemistry.

[9]  F. Menniti,et al.  1‐Aryl‐6,7‐methylenedioxy‐3H‐quinazolin‐4‐ones as Anticonvulsant Agents. , 2004 .

[10]  F. Menniti,et al.  1-aryl-6,7-methylenedioxy-3H-quinazolin-4-ones as anticonvulsant agents. , 2003, Bioorganic & medicinal chemistry letters.

[11]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[12]  R. Shank,et al.  An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of Action , 2000, Epilepsia.

[13]  M. Dichter,et al.  Antiepileptic drug development , 1998 .

[14]  I. Leppik.  Antiepileptic Drugs in Development: Prospects for the Near Future , 1994, Epilepsia.

[15]  M. T. Medina,et al.  Progress in Mapping Human Epilepsy Genes , 1994, Epilepsia.

[16]  W. Löscher,et al.  The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models , 1991, Epilepsy Research.

[17]  J. F. Wolfe,et al.  Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones. , 1990, Journal of medicinal chemistry.

[18]  J. Penry,et al.  Antiepileptic Drug Development: II. Anticonvulsant Drug Screening , 1978, Epilepsia.

[19]  J. Topliss,et al.  A manual method for applying the Hansch approach to drug design. , 1977, Journal of medicinal chemistry.

[20]  J. Lewis,et al.  Probit Analysis (3rd ed). , 1972 .

[21]  N W DUNHAM,et al.  A note on a simple apparatus for detecting neurological deficit in rats and mice. , 1957, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[22]  R. K. Richards,et al.  Pharmacological studies of phenacetylurea (phenurone) an anticonvulsant drug. , 1952, The Journal of pharmacology and experimental therapeutics.

[23]  Woodbury La,et al.  Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. , 1952 .

[24]  V. Davenport,et al.  Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. , 1952, Archives internationales de pharmacodynamie et de therapie.

[25]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.